Get started

Healthcare

Long in NVO Established There are several aspects to this chart- the wave analysis is certainly up for debate, but what remains is improving fundamentals. On this chart we have a corrective sequence ABC starting in 2014 and concluding in early 2017. On this chart, we can see the 30 day MA volume skyrockets in the beginning of 2017. This corresponds to the timing of the Obama administration focusing their healthcare attacks on big pharma, specifically drug pricing. We can even see a faint busted head and shoulders on this chart, with the right shoulder being broken by terrible guidance on earnings At the peak in 2015, we also see a peak in operating profit margin. Over the next 12 month fundamentals began to draw back with book value/share, liquidity ratios, and margins all slowly declining. As Obamacare got pushed through US congress (where over 50% of revenue is earned), the outlook looked bleak. Then the Man who lives above the Guchi Store was elected, and big pharma saw hope on the horizon and began surging higher. This was a false bull market though; margins and liquidity ratios were not improving for NVO. Then the surprise happened, President Trump began attacking pharma. Combined with the already volatile stock market NVO plunged to a correction right at the .618 fibonnaci level, if it maintains this as the low a perfect sign that the 2 impulse wave has just completed. Where we stand now: Novo Nordisk, one of the largest pill pushers was forced to lower outlooks with increasing competition from generics. With this pressure, the company has been forced to cut many US jobs and refocus R&D spending, rendering some patents and research useless. Over the last few years they've been forced to impair assets for use on their income statement, but NVO still maintains a 2.29 P/Tangible Book ratio, (better than peers: GSK, BMY, LLY). Gross margins have begun improving and P/S has landed at one of the lowest, if not the lowest level in the peer group. Improvement on the liquidity measures could send this stock flying, but most importantly is the deadlock that could ensue in congress. Recently one of the up-and-coming generics plunged as the FDA put a hold on their diabetes drug trial. I took a long position in NVO on 11/27 and plan on holding this until I either get stopped out at 44 or we rally to previous highs
NYSE:NVOLong
by scotch321
TORON INC-BIG UPSIDE-LONGTRON is a strong buy. I'm a Technician and only look at charts for my analysis. Analysis Method: Fibonacci & Elliot Waves Thesis: Healthcare is a fragmented market and will be consolidating over the next few years. Technically: Chart has just completed it's first Primary Wave Sequence + Correction. Here is a company overview: Toron Inc. Overview: Acquisition and development of healthcare companies Integrating access to electronic data interfaces for healthcare providers and payer systems Toron, Inc recognizes the tremendous opportunities present in the healthcare space. Zion research recently estimated “global demand for home healthcare market was valued at USD 228.90 billion in 2015 and is expected to generate revenue of USD 391.41 billion by 2021, growing at a CAGR of 9.40% between 2016 and 2021.” Toron, Inc targets the acquisition of additional healthcare focused companies which present excellent shareholder value. Its management has over thirty years combined experience in the healthcare space and it well positioned to identify and rapidly execute its acquisition plans. Toron, Inc intends to operate its business to maximize shareholder value and its management will ensure complete transparency in business operations. In today’s public market confidence is the key ingredient. Management will maintain communication of its operations and future acquisitions, mergers and results from its operations. Toron, Inc (The Company), is engaged in the acquisition and development of healthcare companies for the healthcare supplies and healthcare equipment markets. Management has been engaged in the healthcare technologies and will continue to develop additional markets through healthcare IT and other related entities. toroninc.com Trade Price: .006 Waves: Wave %'s: Indicators: ONB, CMF, Accum/Dist Spirals: Fib Time: Trade:
TLong
by FibMarketWatch
BLRX-BREAKOUT-UPDATEBLRX had a strong rally today and it's just getting started. In the related idea my price target was $1.34. Today's high was $1.78 Check out the weekly chart: Photo Finish. $1.34 was 1.618 extension level from Waves 1 & 2. Since the price-action broke $1.34 we will have an extended 3rd wave. I expect a very strong rally tomorrow, I will update in the morning before the open to confirm. Target is hard to predict since its impossible to know what level extending waves will terminate. I will keep a close eye on the price-action. Will update. -AB
NASDAQ:BLRXLong
by FibMarketWatch
ANAB - "ANAB-tomy" Of A Winning Long Trade?Sorry for the stuffy nose! Nonetheless, here I talk about qualities of a trade that help determine it as a winner. This is just a short version of what to look for, just to give some of the things to consider in the process. As a general statement, there are 2 things that make up a stock: technical factors (price behavior) & fundamental factors (financial statement info). Fundamentals are important for longterm investments where company growth & strength are important, since over time, more people will get interested and buy the stock in the future for further price appreciation (5-10+ years for a solid investment). Simple fundamentals just looks at company profits and how much cash the company has access to, but for a detailed fundamental analysis, the company will need to be known and understood on a very high level as if the investor is one of he founders of the company. Before the investment is made, you must know almost everything about how goods/services reach the consumer/customer. For a trader, correct technical analysis is most important (everyone can do technical analysis, but it takes time to do it in a more realistic fashion without dreaming too much or trying too hard to predict a specific future price action). The more factors that favor your objective to buy the stock, whether as a trade or investment, the more likely you will win from the trade. Here is the list from the video: 1. Technical favor -Price accumulation: price usually builds up slowly before exploding upward in an uptrend, with only few/small price corrections in the trend (it is hard to see this early but it is typically only obvious late AFTER the trend has started) -Volatility contraction-expansion: I talk about this all the time I'll skip it; it is very important to always look for though -Price eagerness to increase: when price keeps trying to push upward to newer levels, this tells that at least there are also other people who see the stock going higher and are willing to put their money on the line for it -Supportive base: the price action should show you that the price has no interest in testing lower levels, which means there are no aggressive sellers, investors or other traders are not selling off and there is a positive sentiment toward the stock -Industry/Sector performance: this was not included in the video, but it usually gives you a great technical context especially when you are diversifying or trying to pick a home run stock (it's still very difficult to pick one though) 2. Fundamental favor (if considering longterm investing) -EPS growth past 3-5yrs (should mirror revenue/net income): this tells you the company's plan to grow/expand and make profit in the process is working, and hence the company is still appealing to old and newer investors -Free cash flow: I didn't explain this well in the video, but I meant to say that a good cash flow means the company has cash on hand aside from other assets to be able to pay off any debt or sudden expenses today if the need arises (this is a very simplified version just to give you an idea) Let's see what ANAB can do! Looking forward to comments or PM discussions.
NASDAQ:ANABEducation
by themdtrader
ENDP - SHORT-TERM SHORT & LONG-TERM BUY - Endo Pharma ENDP Endo International plc is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines through excellence in development, manufacturing and commercialization. Through our operating companies – Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs – Endo is dedicated to serving patients in need. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company. The Crash: Revenue Is In Free Fall Endo Pharmaceuticals: The Free Fall Continues Mar. 26, 2018 Summary Revenue from ENDP's core Generics business is in decline and other business segments appear in disarray. Its $8B debt load is at 7.5x run-rate EBITDA. If operating income continues to slide, it could hurt ENDP's ability to service its debt. ENDP ENDP trades at 9x EBITDA, but it is uncertain if potential legal exposures pursuant to opioids are priced in. Sell ENDP. This idea was discussed in more depth with members of my private investing community, Shocking The Street. There is a war being fought over drug prices. Lawmakers have hit back at price gougers and opioid manufacturers, and Endo Pharmaceuticals (ENDP) is in the middle of it. A few months ago, I thought Endo was at an inflection point and there was a good probability it could turn things around. However, its slide continues. What: The bottom dropped out from under shares of Endo International plc (NASDAQ:ENDP), the specialty pharma famous for selling "uncrushable" opioids and agreeing to enormous legal settlements. After management revealed disturbing revisions of its 2016 full-year estimates, the stock plummeted 41.4% last month, according to data from S&P Global Market Intelligence. Logical? Sold because they sell opiates? Are opiated still needed/critical to US Healthcare? NO! BIG Consolidation period: 4 Years (2014-2018) The First CYCLE WAVE Completed. Now, in the middle of the SECOND WAVE (Correction) Key Levels for Retrace: 1, 1.382, & 1.618 Look for retrace back to around $13.00 ENDP screenshots.firefox.com screenshots.firefox.com screenshots.firefox.com Most Recent News: Endo International Plc (ENDP) on Wednesday said it is lifting a temporary stay of its litigation against the U.S. Food and Drug Administration that seeks a declaration the agency's interim policy on compounding using bulk drug substances is contrary to law. Endo International Plc (ENDP) on Wednesday said it is lifting a temporary stay of its litigation against the U.S. Food and Drug Administration that seeks a declaration the agency's interim policy on compounding using bulk drug substances is contrary to law. Analysts at RBC Capital upgraded Endo International PLC (NASDAQ:ENDP) from Sector Perform to Outperform. Endo shares rose 2.56 percent to $16.05 in pre-market trading. Will update. -Stay humble America, -AB
ELong
by FibMarketWatch
Biogen Earnings Swing July 2018Biogen's (344.10 at close at the date of this writing) and Eisai's recent success with BAN24O1, an experimental medication for Alzheimer's which is currently in mid-stage clinical trials, in addition to a recent price target raise by Citi, and overall bullish analyst sentiment led to a rally between July 6-9, 2018. Although the clinical trial's success was certainly reason for bullish sentiment, it ran too far too fast and indicators pointed towards to a sell off. I thus opened put options on July 9, expiring July 13 2018 (currently in the money). We are now only about two weeks away from Biogen's earning report. After studying historical data and charts, I've found that there is often a sell off prior to earnings OR there is a run up then a slight sell off right before the earnings date. I've annotated the chart with periods that indicate this. In this case, I believe downward momentum will continue followed by a slight rally pre-earnings then a sell off. Opening JUL20 puts may be a smart move at this time. In the long term, Biogen -0.21% is very scalable and overall is very promising. I agree with Citi's PT of 371. www.wsj.com
NASDAQ:BIIBShort
by UnknownUnicorn2997486
ASX:PGC Paragon Healthcare - waiting for a good entry pointASX:PGC Paragon Healthcare seems to be gaining traction and has a slight pull back recently but I would still wait for a clearer signal to enter. A nice cup and handle has been formed and i am waiting for the RSI to cross the 50 mark with conviction before entering. That will also mean I prefer to enter after the prices cross back into the main channel at $0.855 at least. It might be proven to be a little late in future but a stronger signal to enter is still a safer bet. If you decide to enter now, set your stop loss tight at $0.795 or $0.765 depending on your risk appetite. Target set at between $0.96 to $1.045 (ATH). A break below $0.765 will invalidate this view.
ASX:PGC
by paper_value
GlaxoSmithKline ShortShort from $42.01. - Market Cap: $102B - Beta: 0.83 - P/B: 20.42 - GSK’s consumer healthcare segment sales were down in 2017 due to a slowdown in global growth of its key consumer categories. - They have also faced pricing pressure from competition and slow down in emerging markets. Although GSK have several candidates in different stages of development, the company has been set back on numerous occasions by the regulators. The largest setbacks in the past few quarters include the phase 3 data on chronic coronary heart disease, Duchenne muscular dystrophy candidate, kydrisa failing to meet the primary end point in a phase 3 study. - The company phases massive competition from small start-ups to large pharmaceutical corporations. There consumer healthcare segment faces competition from big companies like Johnson & Johnson, Colgate Palmolive, Procter & Gamble and Pfizer. - Advair, one of GSK’s largest revenue providers is facing intense competition in the asthma and COPD market from AstraZeneca and Merck respiratory drugs. NeroTree Capital rates GlaxoSmithKline PLC as a SELL with a price target of $38.
NYSE:GSKShort
by UnknownUnicorn2415222
1
SGYP Is Setting Up for A Big Move!SGYP seems to be setting up for a big big move. The Squeeze Momentum Indicator has been forming a triangle which is now about to close and the crosses in the indicator have been black for some time meaning that a release of the squeeze should be about to manifest. My guess is that spike will be to the upside, and it could go as high as 3.60$ (90%+ appreciation), which is the 0.382 retracement level of 17's highs and the 1.618 retracement level of this year's highs.
SLong
by ArthaVidya
1